Welcome to LookChem.com Sign In|Join Free
  • or
Home > Products > 520 > 

520-52-5

Products Categories

Basic Information
CAS No.: 520-52-5
Name: psilocybine
Article Data: 10
Molecular Structure:
Molecular Structure of 520-52-5 (psilocybine)
Formula: C12H17 N2 O4 P
Molecular Weight: 284.252
Synonyms: 1H-Indol-4-ol,3-[2-(dimethylamino)ethyl]-, dihydrogen phosphate (ester) (9CI);Indol-4-ol,3-(2-dimethylaminoethyl)-, phosphate (6CI);Indol-4-ol,3-[2-(dimethylamino)ethyl]-, dihydrogen phosphate (ester) (8CI);3-(2-Dimethylaminoethyl)indol-4-yl dihydrogen phosphate;4-Phosphoryl-N,N-dimethyltryptamine;Cy 39;Indocybin;O-Phosphoryl-4-hydroxy-N,N-dimethyltryptamine;Psilocine phosphate;Psilocybin;Psilocybine;Psylocybin;
EINECS: 208-294-4
Density: 1.409g/cm3
Melting Point: 220-2280C
Boiling Point: 523.4°Cat760mmHg
Flash Point: 270.4°C
Safety: Poison by intravenous route. Moderately toxic by intraperitoneal route. Human systemic effects by ingestion and intraperitoneal routes: euphoria, hallucinations, toxic psychosis, muscle weakness, nausea or vomiting, visual field changes. Mutation data reported. When heated to decomposition it emits very toxic fumes of NOx and POx.
PSA: 95.60000
LogP: 1.74350
  • Display:default sort

    New supplier

This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.

Consensus Reports

EPA Genetic Toxicology Program.

Specification

 The Psilocybine, with the CAS registry number 520-52-5,is also known as 3-(2-(Dimethylamino)ethyl)-1H-indol-4-ol dihydrogen phosphate ester. It belongs to the product categories of Intermediates & Fine Chemicals;Pharmaceuticals.This chemical's molecular formula is C12H17N2O4P and molecular weight is 284.25. What's more,Its systematic name is Psilocybine.It is Crystallin Solid ,which is the major of two hallucinogenic components of Teonanacatl, the sacred mushroom of Mexico, the other component being psilocin.

Physical properties about Psilocybine are:
(1)ACD/LogP:  0.72; (2)# of Rule of 5 Violations:  0; (3)ACD/LogD (pH 5.5):  -1.78; (4)ACD/LogD (pH 7.4):  -1.95; (5)ACD/BCF (pH 5.5):  1.00; (6)ACD/BCF (pH 7.4):  1.00; (7)ACD/KOC (pH 5.5):  1.00; (8)ACD/KOC (pH 7.4):  1.00; (9)#H bond acceptors:  6; (10)#H bond donors:  3; (11)#Freely Rotating Bonds:  5; (12)Index of Refraction:  1.645; (13)Molar Refractivity:  73.054 cm3; (14)Molar Volume:  201.61 cm3; (15)Surface Tension:  66.1719970703125 dyne/cm; (16)Density:  1.41 g/cm3; (17)Flash Point:  270.369 °C; (18)Enthalpy of Vaporization:  83.913 kJ/mol; (19)Boiling Point:  523.443 °C at 760 mmHg; (20)Vapour Pressure:  0 mmHg at 25°C.

You can still convert the following datas into molecular structure:
(1)SMILES:O=P(O)(O)Oc1cccc2c1c(cn2)CCN(C)C;
(2)Std. InChI:InChI=1S/C12H17N2O4P/c1-14(2)7-6-9-8-13-10-4-3-5-11(12(9)10)18-19(15,16)17/h3-5,8,13H,6-7H2,1-2H3,(H2,15,16,17);
(3)Std. InChIKey:QVDSEJDULKLHCG-UHFFFAOYSA-N.

Safety Information of Psilocybine:
Poison by intravenous route. Moderately toxic by intraperitoneal route. Human systemic effects by ingestion and intraperitoneal routes: euphoria, hallucinations, toxic psychosis, muscle weakness, nausea or vomiting, visual field changes. Mutation data reported. When heated to decomposition it emits very toxic fumes of NOx and POx.

The toxicity data of Psilocybine as follows:

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
human TDLo intramuscular 75ug/kg (0.075mg/kg) BEHAVIORAL: EUPHORIA

BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS"
Psychopharmacologia Vol. 3, Pg. 219, 1962.
human TDLo intramuscular 130ug/kg (0.13mg/kg) BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS"

BEHAVIORAL: TOXIC PSYCHOSIS
Proceedings of the European Society for the Study of Drug Toxicity. Vol. 8, Pg. 59, 1967.
human TDLo intraperitoneal 37ug/kg (0.037mg/kg) SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE

BEHAVIORAL: MUSCLE WEAKNESS

GASTROINTESTINAL: NAUSEA OR VOMITING
Journal of Nervous and Mental Disease. Vol. 131, Pg. 428, 1960.
human TDLo oral 60ug/kg (0.06mg/kg) SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE

BEHAVIORAL: MUSCLE WEAKNESS

GASTROINTESTINAL: NAUSEA OR VOMITING
Journal of Nervous and Mental Disease. Vol. 131, Pg. 428, 1960.
mouse LD50 intraperitoneal 420mg/kg (420mg/kg) SENSE ORGANS AND SPECIAL SENSES: MYDRIASIS (PUPILLARY DILATION): EYE

GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. Vol. 64, Pg. 159, 1968.
mouse LD50 intravenous 275mg/kg (275mg/kg) SENSE ORGANS AND SPECIAL SENSES: MYDRIASIS (PUPILLARY DILATION): EYE

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS
Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. Vol. 64, Pg. 159, 1968.
rabbit LD50 intravenous 13mg/kg (13mg/kg)   "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 138, 1972.
rat LD50 intravenous 280mg/kg (280mg/kg)   "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 138, 1972.